Mineralys Therapeutics, Inc. Common Stock (MLYS) Stock
NASDAQ · MLYS
28.31
Fundamentals
Market cap
$2.48B
Price / Earnings ratio
-7.1x
Price / Sales ratio
N/A
Price / Book ratio
4.5x
Return on assets
-0.3%
Ex-Dividend date
N/A
Last payment date
N/A
Dividend amount
$0.00
Dividend yield
0.0%
Debt / Equity ratio
N/A
Latest news
About Mineralys Therapeutics, Inc. Common Stock
No description available.
SectorHealthcare
IndustryBiotechnology
Employees76
CEODr. Jon Congleton
IPO DateFeb 8, 2023
HeadquartersRadnor, PA
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Jon Congleton | President, CEO & Director | 1963 |
| Dr. Brian Taylor Slingsby M.D., M.P.H., Ph.D. | Founder & Executive Director | 1977 |
| Mr. Adam Scott Levy | CFO & Secretary | 1978 |
| Mr. Jeffrey A. Munsie J.D. | Chief Legal Officer | 1977 |
| Dr. Robert McKean Ph.D. | Senior Vice President of CMC | — |
| Ms. Danielle Mahoney | Senior Vice President of Quality Assurance | — |
| Ms. Jessica Ibbitson | Executive Vice President of Operations | — |
| Mr. Eric J. Warren R.Ph. | Chief Commercial Officer | 1972 |
| Mr. Michael Tortorici Ph.D., Pharm.D. | Senior Vice President of Translational Medicine | — |
| Dr. James J. Ferguson III, FACC, M.D. | Chief Medical Officer | 1954 |
Fundamentals
Valuation
Market cap$2.48B
Price-to-sales ratioN/A
Price-to-book value4.50
Price-earnings ratio-7.10
Return on Equity-28.00%
Return on SalesN/A
Return on AssetsN/A
PEG ratioN/A
Earnings Per Share
Earnings Per Share$-4.19
Income Statement
Average volume1,321,521
EBITDA$-151.73M
1 year high (52w)$47.65
1 year low (52w)$22.30
Dividend
Ex dividend dateN/A
Dividend amount$0.00
Dividend yield0.00%
Last payment dateN/A
Dividend yield (TTM)N/A
Next earnings reportN/A
Solvency
Debt-to-equity ratioN/A



